Russia’s competition authority approved of Sistema’s buyout of Veropharm on Monday, and, as a result, shares surged in the Moscow stock exchange for two of nation’s pharmaceutical companies, Veropharm and 36.6. Shares in 36.6 rose 6.7 percent, while shares for Veroharm – Russia’s third largest drug maker – rose 9.7 percent. 36.6 had previously announced it was ready to sell its share in Veropharm, which amounted to 51.8 percent of the company, to pay off debts. Russia’s Federal Anti-Monopoly Service has approved of the merger as long as certain conditions are met, though there is no word yet on what those conditions are.
Full Content: RiaNovosti
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Nvidia’s $700 Million Buyout of Run:ai Gets EU Approval, Deal Finalized
Jan 1, 2025 by
CPI
Taiwan FTC Halts Uber’s $950M Foodpanda Buyout Over Antitrust Fears
Jan 1, 2025 by
CPI
White House Pushes for Stronger Healthcare Data Security
Jan 1, 2025 by
CPI
Microsoft’s Cybersecurity Bundles Draw Antitrust Inquiry
Jan 1, 2025 by
CPI
UK Watchdog to Review IBM’s $6.4 Billion Acquisition of HashiCorp
Jan 1, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand